Which has higher earnings & valuation, QNCX or IMNN?

Imunon is trading at a lower price-to-earnings ratio than Quince Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Quince Therapeutics N/A N/A -$83.98M -$156.71 N/A Imunon N/A N/A -$14.49M -$3.83 N/A

Is QNCX or IMNN more profitable?

Quince Therapeutics' return on equity of 0.00% beat Imunon's return on equity. Company Net Margins Return on Equity Return on Assets Quince Therapeutics N/A N/A -133.84% Imunon N/A -358.01% -132.91%

Does the media favor QNCX or IMNN?

In the previous week, Imunon had 5 more articles in the media than Quince Therapeutics. MarketBeat recorded 10 mentions for Imunon and 5 mentions for Quince Therapeutics. Quince Therapeutics' average media sentiment score of 0.45 beat Imunon's score of 0.42 indicating that Quince Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Quince Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Imunon 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend IMNN or BYSI?

Imunon presently has a consensus target price of $10.00, suggesting a potential upside of 513.50%. Given Imunon's stronger consensus rating and higher probable upside, equities analysts plainly believe Imunon is more favorable than BeyondSpring. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Imunon 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 BeyondSpring 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is IMNN or BYSI more profitable?

BeyondSpring's return on equity of 0.00% beat Imunon's return on equity. Company Net Margins Return on Equity Return on Assets Imunon N/A -358.01% -132.91% BeyondSpring N/A N/A -28.88%

Is ATNM or IMNN more profitable?

Actinium Pharmaceuticals' return on equity of -100.85% beat Imunon's return on equity. Company Net Margins Return on Equity Return on Assets Actinium Pharmaceuticals N/A -100.85% -47.89% Imunon N/A -358.01% -132.91%

Do analysts prefer LTRN or IMNN?

Imunon has a consensus price target of $10.00, indicating a potential upside of 513.50%. Given Imunon's stronger consensus rating and higher probable upside, analysts clearly believe Imunon is more favorable than Lantern Pharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lantern Pharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Imunon 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has higher earnings & valuation, LTRN or IMNN?

Lantern Pharma is trading at a lower price-to-earnings ratio than Imunon, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Lantern Pharma N/A N/A -$17.12M -$1.62 N/A Imunon N/A N/A -$14.49M -$3.83 N/A

Is LTRN or IMNN more profitable?

Imunon's return on equity of -358.01% beat Lantern Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Lantern Pharma N/A -368.02% -148.62% Imunon N/A -358.01% -132.91%

Does the media prefer LTRN or IMNN?

In the previous week, Imunon had 8 more articles in the media than Lantern Pharma. MarketBeat recorded 10 mentions for Imunon and 2 mentions for Lantern Pharma. Lantern Pharma's average media sentiment score of 0.94 beat Imunon's score of 0.42 indicating that Lantern Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lantern Pharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Imunon 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better valuation and earnings, IMNN or ESLA?

Estrella Immunopharma is trading at a lower price-to-earnings ratio than Imunon, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Imunon N/A N/A -$14.49M -$3.83 N/A Estrella Immunopharma N/A N/A -$13.06M -$0.24 N/A

Is IMNN or ESLA more profitable?

Estrella Immunopharma's return on equity of 0.00% beat Imunon's return on equity. Company Net Margins Return on Equity Return on Assets Imunon N/A -358.01% -132.91% Estrella Immunopharma N/A N/A -328.72%

Does the media prefer IMNN or ESLA?

In the previous week, Imunon had 7 more articles in the media than Estrella Immunopharma. MarketBeat recorded 10 mentions for Imunon and 3 mentions for Estrella Immunopharma. Estrella Immunopharma's average media sentiment score of 0.63 beat Imunon's score of 0.42 indicating that Estrella Immunopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Imunon 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Estrella Immunopharma 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Imunon (IMNN) Competitors

$1.63 -0.03 (-1.81%)

As of 04:00 PM Eastern

Compare

IMNN vs. QNCX, BYSI, ATNM, LTRN, and ESLA

Should you buy Imunon stock or one of its competitors? Imunon's main competitors and comparable companies include Quince Therapeutics (QNCX), BeyondSpring (BYSI), Actinium Pharmaceuticals (ATNM), Lantern Pharma (LTRN), and Estrella Immunopharma (ESLA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Imunon compare to Quince Therapeutics?

Quince Therapeutics (NASDAQ:QNCX) and Imunon (NASDAQ:IMNN) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, media sentiment, risk, earnings, dividends, valuation, profitability and analyst recommendations.

Imunon is trading at a lower price-to-earnings ratio than Quince Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Quince Therapeutics	N/A	N/A	-$83.98M	-$156.71	N/A
Imunon	N/A	N/A	-$14.49M	-$3.83	N/A

Quince Therapeutics presently has a consensus target price of $260.00, indicating a potential upside of 730.41%. Imunon has a consensus target price of $10.00, indicating a potential upside of 513.50%. Given Quince Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Quince Therapeutics is more favorable than Imunon.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Quince Therapeutics	2 Sell rating(s)	5 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.33
Imunon	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Quince Therapeutics has a beta of 1.36, meaning that its stock price is 36% more volatile than the broader market. Comparatively, Imunon has a beta of 1.97, meaning that its stock price is 97% more volatile than the broader market.

In the previous week, Imunon had 5 more articles in the media than Quince Therapeutics. MarketBeat recorded 10 mentions for Imunon and 5 mentions for Quince Therapeutics. Quince Therapeutics' average media sentiment score of 0.45 beat Imunon's score of 0.42 indicating that Quince Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Quince Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Imunon	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

30.8% of Quince Therapeutics shares are held by institutional investors. Comparatively, 4.5% of Imunon shares are held by institutional investors. 7.1% of Quince Therapeutics shares are held by company insiders. Comparatively, 2.8% of Imunon shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Quince Therapeutics' return on equity of 0.00% beat Imunon's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Quince Therapeutics	N/A	N/A	-133.84%
Imunon	N/A	-358.01%	-132.91%

Summary

Quince Therapeutics beats Imunon on 9 of the 14 factors compared between the two stocks.

How does Imunon compare to BeyondSpring?

Imunon (NASDAQ:IMNN) and BeyondSpring (NASDAQ:BYSI) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, profitability, dividends, analyst recommendations, earnings, institutional ownership, media sentiment and risk.

Imunon presently has a consensus target price of $10.00, suggesting a potential upside of 513.50%. Given Imunon's stronger consensus rating and higher probable upside, equities analysts plainly believe Imunon is more favorable than BeyondSpring.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Imunon	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
BeyondSpring	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

BeyondSpring has higher revenue and earnings than Imunon. BeyondSpring is trading at a lower price-to-earnings ratio than Imunon, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Imunon	N/A	N/A	-$14.49M	-$3.83	N/A
BeyondSpring	$1.75M	16.21	-$1.01M	-$0.12	N/A

In the previous week, Imunon had 9 more articles in the media than BeyondSpring. MarketBeat recorded 10 mentions for Imunon and 1 mentions for BeyondSpring. BeyondSpring's average media sentiment score of 1.89 beat Imunon's score of 0.42 indicating that BeyondSpring is being referred to more favorably in the news media.

Company	Overall Sentiment
Imunon	Neutral
BeyondSpring	Very Positive

Imunon has a beta of 1.97, meaning that its share price is 97% more volatile than the broader market. Comparatively, BeyondSpring has a beta of 0.48, meaning that its share price is 52% less volatile than the broader market.

4.5% of Imunon shares are owned by institutional investors. Comparatively, 40.3% of BeyondSpring shares are owned by institutional investors. 2.8% of Imunon shares are owned by insiders. Comparatively, 29.3% of BeyondSpring shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

BeyondSpring's return on equity of 0.00% beat Imunon's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Imunon	N/A	-358.01%	-132.91%
BeyondSpring	N/A	N/A	-28.88%

Summary

BeyondSpring beats Imunon on 8 of the 14 factors compared between the two stocks.

How does Imunon compare to Actinium Pharmaceuticals?

Actinium Pharmaceuticals (NYSE:ATNM) and Imunon (NASDAQ:IMNN) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, profitability, dividends, media sentiment, risk, institutional ownership, earnings and analyst recommendations.

27.5% of Actinium Pharmaceuticals shares are owned by institutional investors. Comparatively, 4.5% of Imunon shares are owned by institutional investors. 0.6% of Actinium Pharmaceuticals shares are owned by company insiders. Comparatively, 2.8% of Imunon shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Imunon had 10 more articles in the media than Actinium Pharmaceuticals. MarketBeat recorded 10 mentions for Imunon and 0 mentions for Actinium Pharmaceuticals. Imunon's average media sentiment score of 0.42 beat Actinium Pharmaceuticals' score of 0.00 indicating that Imunon is being referred to more favorably in the news media.

Company	Overall Sentiment
Actinium Pharmaceuticals	Neutral
Imunon	Neutral

Actinium Pharmaceuticals has a beta of 0.01, meaning that its share price is 99% less volatile than the broader market. Comparatively, Imunon has a beta of 1.97, meaning that its share price is 97% more volatile than the broader market.

Actinium Pharmaceuticals currently has a consensus target price of $5.00, suggesting a potential upside of 395.05%. Imunon has a consensus target price of $10.00, suggesting a potential upside of 513.50%. Given Imunon's higher possible upside, analysts clearly believe Imunon is more favorable than Actinium Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Actinium Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Imunon	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Actinium Pharmaceuticals' return on equity of -100.85% beat Imunon's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Actinium Pharmaceuticals	N/A	-100.85%	-47.89%
Imunon	N/A	-358.01%	-132.91%

Imunon has lower revenue, but higher earnings than Actinium Pharmaceuticals. Imunon is trading at a lower price-to-earnings ratio than Actinium Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Actinium Pharmaceuticals	$35.09M	0.90	-$48.82M	$0.36	2.81
Imunon	N/A	N/A	-$14.49M	-$3.83	N/A

Summary

Imunon beats Actinium Pharmaceuticals on 7 of the 13 factors compared between the two stocks.

How does Imunon compare to Lantern Pharma?

Lantern Pharma (NASDAQ:LTRN) and Imunon (NASDAQ:IMNN) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, dividends, risk, profitability, media sentiment, analyst recommendations and institutional ownership.

Imunon has a consensus price target of $10.00, indicating a potential upside of 513.50%. Given Imunon's stronger consensus rating and higher probable upside, analysts clearly believe Imunon is more favorable than Lantern Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lantern Pharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Imunon	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Imunon's return on equity of -358.01% beat Lantern Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lantern Pharma	N/A	-368.02%	-148.62%
Imunon	N/A	-358.01%	-132.91%

Lantern Pharma has a beta of 2.34, indicating that its stock price is 134% more volatile than the broader market. Comparatively, Imunon has a beta of 1.97, indicating that its stock price is 97% more volatile than the broader market.

In the previous week, Imunon had 8 more articles in the media than Lantern Pharma. MarketBeat recorded 10 mentions for Imunon and 2 mentions for Lantern Pharma. Lantern Pharma's average media sentiment score of 0.94 beat Imunon's score of 0.42 indicating that Lantern Pharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lantern Pharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Imunon	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

28.6% of Lantern Pharma shares are owned by institutional investors. Comparatively, 4.5% of Imunon shares are owned by institutional investors. 8.5% of Lantern Pharma shares are owned by insiders. Comparatively, 2.8% of Imunon shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Lantern Pharma is trading at a lower price-to-earnings ratio than Imunon, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lantern Pharma	N/A	N/A	-$17.12M	-$1.62	N/A
Imunon	N/A	N/A	-$14.49M	-$3.83	N/A

Summary

Imunon beats Lantern Pharma on 8 of the 13 factors compared between the two stocks.

How does Imunon compare to Estrella Immunopharma?

Imunon (NASDAQ:IMNN) and Estrella Immunopharma (NASDAQ:ESLA) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, dividends, analyst recommendations, institutional ownership, valuation, risk, earnings and media sentiment.

Estrella Immunopharma is trading at a lower price-to-earnings ratio than Imunon, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Imunon	N/A	N/A	-$14.49M	-$3.83	N/A
Estrella Immunopharma	N/A	N/A	-$13.06M	-$0.24	N/A

Imunon presently has a consensus target price of $10.00, indicating a potential upside of 513.50%. Estrella Immunopharma has a consensus target price of $8.00, indicating a potential upside of 995.89%. Given Estrella Immunopharma's higher probable upside, analysts plainly believe Estrella Immunopharma is more favorable than Imunon.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Imunon	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Estrella Immunopharma	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Imunon has a beta of 1.97, meaning that its share price is 97% more volatile than the broader market. Comparatively, Estrella Immunopharma has a beta of 0.88, meaning that its share price is 12% less volatile than the broader market.

4.5% of Imunon shares are held by institutional investors. Comparatively, 0.4% of Estrella Immunopharma shares are held by institutional investors. 2.8% of Imunon shares are held by company insiders. Comparatively, 5.8% of Estrella Immunopharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Estrella Immunopharma's return on equity of 0.00% beat Imunon's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Imunon	N/A	-358.01%	-132.91%
Estrella Immunopharma	N/A	N/A	-328.72%

In the previous week, Imunon had 7 more articles in the media than Estrella Immunopharma. MarketBeat recorded 10 mentions for Imunon and 3 mentions for Estrella Immunopharma. Estrella Immunopharma's average media sentiment score of 0.63 beat Imunon's score of 0.42 indicating that Estrella Immunopharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Imunon	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Estrella Immunopharma	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Estrella Immunopharma beats Imunon on 6 of the 11 factors compared between the two stocks.

Get Imunon News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IMNN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IMNN vs. The Competition

Export

Metric	Imunon	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$9.14M	$4.03B	$7.30B	$12.77B
Dividend Yield	N/A	3.63%	2.53%	10.79%
P/E Ratio	-0.43	11.42	272.49	24.13
Price / Sales	N/A	1,366.67	626.71	98.17
Price / Cash	N/A	103.64	78.57	53.12
Price / Book	4.66	16.88	13.14	6.23
Net Income	-$14.49M	-$22.76M	$3.47B	$348.07M
7 Day Performance	3.16%	1.55%	1.38%	0.66%
1 Month Performance	7.95%	11.71%	8.62%	4.84%
1 Year Performance	-73.88%	56.88%	25.90%	16.83%

Imunon Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IMNN Imunon	3.1614 of 5 stars	$1.63 -1.8%	$10.00 +513.5%	-73.9%	$9.14M	N/A	N/A	30
QNCX Quince Therapeutics	2.6707 of 5 stars	$32.91 -3.5%	$308.00 +835.9%	-90.2%	$34.70M	N/A	N/A	60	Gap Up
BYSI BeyondSpring	0.4457 of 5 stars	$0.72 +0.9%	N/A	-60.4%	$34.50M	$1.75M	N/A	80	Positive News Gap Down
ATNM Actinium Pharmaceuticals	1.8893 of 5 stars	$1.08 +2.9%	$5.00 +363.0%	-39.7%	$33.96M	$35.09M	N/A	30
LTRN Lantern Pharma	0.5281 of 5 stars	$2.52 -3.1%	N/A	-52.3%	$33.81M	N/A	N/A	20	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IMNN) was last updated on 8/26/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Imunon (IMNN) Competitors

IMNN vs. QNCX, BYSI, ATNM, LTRN, and ESLA

How does Imunon compare to Quince Therapeutics?

Summary

How does Imunon compare to BeyondSpring?

Summary

How does Imunon compare to Actinium Pharmaceuticals?

Summary

How does Imunon compare to Lantern Pharma?

Summary

How does Imunon compare to Estrella Immunopharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMNN vs. The Competition

Imunon Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Imunon (IMNN) Competitors

IMNN vs. QNCX, BYSI, ATNM, LTRN, and ESLA

How does Imunon compare to Quince Therapeutics?

Which has higher earnings & valuation, QNCX or IMNN?

Do analysts recommend QNCX or IMNN?

Which has more volatility and risk, QNCX or IMNN?

Does the media favor QNCX or IMNN?

Do insiders & institutionals have more ownership in QNCX or IMNN?

Is QNCX or IMNN more profitable?

Summary

How does Imunon compare to BeyondSpring?

Do analysts recommend IMNN or BYSI?

Which has better valuation & earnings, IMNN or BYSI?

Does the media refer more to IMNN or BYSI?

Which has more risk and volatility, IMNN or BYSI?

Do insiders & institutionals hold more shares of IMNN or BYSI?

Is IMNN or BYSI more profitable?

Summary

How does Imunon compare to Actinium Pharmaceuticals?

Do institutionals and insiders have more ownership in ATNM or IMNN?

Does the media prefer ATNM or IMNN?

Which has more volatility & risk, ATNM or IMNN?

Do analysts rate ATNM or IMNN?

Is ATNM or IMNN more profitable?

Which has better earnings and valuation, ATNM or IMNN?

Summary

How does Imunon compare to Lantern Pharma?

Do analysts prefer LTRN or IMNN?

Is LTRN or IMNN more profitable?

Which has more risk & volatility, LTRN or IMNN?

Does the media prefer LTRN or IMNN?

Do institutionals & insiders have more ownership in LTRN or IMNN?

Which has higher earnings & valuation, LTRN or IMNN?

Summary

How does Imunon compare to Estrella Immunopharma?

Which has better valuation and earnings, IMNN or ESLA?

Do analysts prefer IMNN or ESLA?

Which has more risk & volatility, IMNN or ESLA?

Do insiders and institutionals believe in IMNN or ESLA?

Is IMNN or ESLA more profitable?

Does the media prefer IMNN or ESLA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMNN vs. The Competition

Imunon Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools